Highlights Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Delayed Nasdaq Other stock markets 03:13:38 2024-05-03 pm EDT			5-day change	1st Jan Change
3.83 ^USD	-4.01%		-5.90%	-10.30%

Apr. 10	Bryant D. Lim to Serve as Principal Financial Officer and Principal Accounting Officer of Prelude Therapeutics Incorporated	CI
Apr. 10	Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference	23-10-14	CI
Prelude Therapeutics Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Debt Ceiling Deal Hopes Boost Exchange-Traded Funds, Equity Futures Pre-Bell Thursday	23-05-18	MT
PRELUDE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-08	AQ
Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Prelude Therapeutics Forms Hematologic Cancer Clinical Trial Partnership with BeiGene	23-03-15	MT
PRELUDE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-15	AQ
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Prelude Therapeutics Incorporated Announces Clinical Trial Collaboration with BeiGene	23-03-15	CI
PRELUDE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-14	AQ
Earnings Flash (PRLD) PRELUDE THERAPEUTICS Reports Q3 Loss $-0.63	22-11-14	MT
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter Ended September 30, 2022	22-11-14	CI
Prelude Therapeutics Incorporated Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader	22-10-18	CI
PRELUDE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-09	AQ
Prelude Therapeutics Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
PRELUDE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-05-10	AQ
Earnings Flash (PRLD) PRELUDE THERAPEUTICS Posts Q1 Loss $-0.63	22-05-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Highlights

Filters